Add office photos
Employer?
Claim Account for FREE
Memorial Sloan Kettering Cancer Center
3.2
based on 5 Reviews
Working at Memorial Sloan Kettering Cancer Center
Company Summary
Overall Rating
3.2/5
based on 5 reviews
Highly rated for
Work-life balance, Work satisfaction
Critically rated for
Promotions, Skill development, Salary
About Memorial Sloan Kettering Cancer Center
Founded in--
India Employee Count--
Global Employee Count--
Headquarters--
Office Locations
--
Websitemskcc.org
Primary Industry
--
Other Industries
--
Are you managing Memorial Sloan Kettering Cancer Center's employer brand? To edit company information,
claim this page for free
Managing your company's employer brand?
Claim this Company Page for FREE
Memorial Sloan Kettering Cancer Center Ratings
based on 5 reviews
Overall Rating
3.2/5
How AmbitionBox ratings work?
5
2
4
1
3
1
2
0
1
1
Category Ratings
4.2
Work-life balance
3.8
Work satisfaction
3.5
Company culture
3.2
Job security
3.2
Salary
2.8
Skill development
2.8
Promotions
Memorial Sloan Kettering Cancer Center is rated 3.2 out of 5 stars on AmbitionBox, based on 5 company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Memorial Sloan Kettering Cancer Center Reviews
Compare Memorial Sloan Kettering Cancer Center with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.2/5 based on 5 reviews | 3.7/5 based on 91.1k reviews | 3.7/5 based on 53.8k reviews | 3.8/5 based on 57.4k reviews |
Highly Rated for | Work-life balance Work satisfaction | Job security Work-life balance | Job security | Job security Company culture |
Critically Rated for | Skill development Promotions Salary | Promotions Salary Work satisfaction | Promotions Salary | Promotions |
Primary Work Policy | - | Work from office 81% employees reported | Hybrid 62% employees reported | Hybrid 74% employees reported |
Rating by Women Employees | 2.1 Poor rated by 2 women | 3.7 Good rated by 26.4k women | 3.8 Good rated by 15.4k women | 3.9 Good rated by 21.6k women |
Rating by Men Employees | 4.0 Good rated by 3 men | 3.6 Good rated by 59.5k men | 3.7 Good rated by 36k men | 3.8 Good rated by 33.3k men |
Job security | 3.2 Average | 4.5 Good | 3.8 Good | 3.8 Good |
View more
Memorial Sloan Kettering Cancer Center Salaries
Memorial Sloan Kettering Cancer Center salaries have received with an average score of 3.2 out of 5 by 5 employees.
Front Office Administrator
(1 salaries)
Unlock
₹6.5 L/yr - ₹8.3 L/yr
Research Associate
(1 salaries)
Unlock
₹37.8 L/yr - ₹48.3 L/yr
Medical Doctor
(1 salaries)
Unlock
₹4.5 L/yr - ₹5.8 L/yr
Research Technician
(1 salaries)
Unlock
₹31.5 L/yr - ₹40.2 L/yr
Memorial Sloan Kettering Cancer Center News
Revolutionary Cryo-Electron Microscopy Unlocks Secrets of DNA Replication and Illuminates New Cancer Treatment Targets
- DNA replication is a crucial process guided by genetic material, but replication stress can lead to errors and diseases like cancer.
- G-quadruplexes, unique DNA structures, pose challenges during replication and offer potential cancer treatment targets.
- Research at Memorial Sloan Kettering Cancer Center used cryo-electron microscopy to study G-quadruplexes' role in DNA replication.
- Findings published in Science shed light on how replisomes navigate around G-quadruplex obstacles during replication.
- G-quadruplexes have evolutionary flexibility and are recognized for disrupting cancer-promoting genes like MYC and KRAS.
- Understanding G4 structures' impact on DNA replication is essential for developing targeted cancer treatments.
- Study revealed the CMG helicase's unique helical inchworm motion, challenging conventional enzyme movement models.
- Insights into G-quadruplex behavior offer new avenues for therapeutic development in cancer treatment.
- Identification of G-quadruplexes as contributors to genomic instability can inform broader cancer research strategies.
- Continued research on G4 structures is crucial for enhancing comprehension of cancer biology and therapeutic innovations.
Bioengineer | 10 Mar, 2025
Lifesaving cancer study delivers complete remission for all trial patients
- In a groundbreaking clinical trial, immunotherapy alone eliminated rectal cancer in all 14 participants, marking a significant advancement in cancer treatment.
- The trial targeted non-metastatic rectal cancer patients with a specific genetic mutation, achieving complete remission in every participant.
- Memorial Sloan Kettering Cancer Center researchers reported that patients remained cancer-free for over two years after treatment.
- Immunotherapy has the potential to replace chemotherapy, radiation, and surgery for certain rectal cancers, reducing severe side effects associated with traditional treatments.
- The trial focused on tumors with mismatch repair-deficient or microsatellite instability genetic signatures, enabling the immune system to recognize and attack cancer cells.
- Participants in the study received a checkpoint inhibitor, preventing the suppression of the immune response by the PD-1 protein on T-cells.
- The unprecedented results showed full remission in all patients, emphasizing the efficacy of immunotherapy as a first-line treatment for rectal cancer.
- The findings offer hope for improved outcomes and reduced toxicities in rectal cancer patients compared to conventional treatments.
- Ongoing research continues to explore immunotherapy's potential as a primary treatment for rectal cancer, with significant interest in the medical community.
- The study signifies a breakthrough in rectal cancer treatment and sets the stage for future investigations into using immunotherapy for cancer treatment.
Brighter Side of News | 7 Mar, 2025
MSK to Deploy Abridge’s AI Oncology Clinical Documentation
- Memorial Sloan Kettering Cancer Center (MSK) will deploy Abridge's AI platform to support clinical conversations.
- Abridge's AI platform converts medical conversations into clinically useful and billable documentation at the point of care.
- The platform demonstrated accuracy in capturing oncology-specific terminology and supporting multilingual encounters.
- Abridge's AI platform empowers clinicians to focus on patient interactions and enhances documentation accuracy across leading health systems.
Hitconsultant | 7 Mar, 2025
Discoveries from MSK Research: Highlights and Innovations – February 13, 2025
- Memorial Sloan Kettering Cancer Center (MSK) is at the forefront of innovative cancer research, focusing on resistance mechanisms, novel treatment paradigms, and AI integration for patient care enhancement.
- FDA's approval of datopotamab deruxtecan for ER-positive, HER2-negative breast cancer marks a significant advancement, offering improved response rates and progression-free survival over conventional chemotherapy.
- Research on resistance mechanisms led by MSK's surgeon-scientist Brett S. Carver reveals mTOR pathway's role in PTEN-deficient prostate cancers' resistance to targeted treatments, paving the way for combination therapy strategies.
- MSK's study on FBXO45 protein in B-cell lymphomas sheds light on ubiquitin-mediated degradation's impact and potential sensitization to MEK inhibition, suggesting new targeted therapeutic approaches.
- Integration of ChatGPT-style AI models for patient-reported outcomes shows promise in capturing nuanced patient experiences in oncology practices, potentially revolutionizing data collection methods and treatment understanding.
- Education on palliative care principles for emergency department practitioners through MSK's initiative aims to improve patient outcomes and shift towards home or hospice care, emphasizing the need for sensitive, value-aligned decisions.
- MSK's focus on multidisciplinary approaches, advanced therapeutics, and technological advancements signifies a future where cancer treatment not only improves survival rates but also enhances quality of life for patients.
- The collaborative efforts at MSK highlight transformative possibilities in cancer management, showcasing the importance of ongoing research refinement and innovation in the fight against cancer.
- These breakthroughs emphasize the dynamic nature of cancer research, with the potential to lead to personalized and effective treatment protocols, signaling a new era in cancer care.
- As MSK continues to drive progress in cancer research, the collective efforts within the scientific community hold promise for ushering in a future characterized by novel therapies and enhanced patient care.
Bioengineer | 14 Feb, 2025
February 6, 2025: Key Insights from MSK Research
- MSK researchers highlight diverse advancements in rare cancer treatment, from innovative cell therapies to enhanced drug delivery using nanoparticles.
- The clinical trial investigating TCR therapy (letetresgene autoleucel) has shown remarkable promise for advanced myxoid/round cell liposarcoma patients.
- The study led by Dr. Jae Park revealed encouraging results for patients diagnosed with large B cell lymphoma
- Researchers are making significant strides in the field of nanoparticle drug delivery systems, exploring the encapsulation of therapeutic agents within nanoparticles to enhance their efficiency while minimizing systemic exposure.
- Moreover, researchers at MSK have turned their attention to novel methodologies for engineering CAR T cells capable of specifically activating within tumor microenvironments.
- Researchers have noted that in rare instances, CAR T cell treatments may inadvertently result in the emergence of new malignancies.
- As this tapestry of research unfolds, it becomes increasingly evident that we are on the cusp of a new era in cancer treatment - championing innovation, patient-tailored therapies, and an informed understanding of the interplay between cancer and immune responses.
- The future holds promise, yet it is through diligence, research and collective dedication to improving patient outcomes that we can navigate the complexities of cancer treatment with success.
- These developments at Memorial Sloan Kettering Cancer Center signify a monumental collective effort in redefining cancer therapeutics.
- As researchers continue to explore and refine these innovative treatments, the balance of efficacy and safety remains central to the advancements in cancer care and will undoubtedly shape the landscape for years to come.
Bioengineer | 7 Feb, 2025
A new era in cancer research: AI superclusters accelerate breakthroughs
- AI superclusters in cancer research are accelerating breakthroughs and transforming patient care.
- Memorial Sloan Kettering Cancer Center's artificial intelligence supercluster, called the Cluster of Discovery, has reduced research timelines by 30 times.
- Partnerships between MSK, Dell, and Weka have created an infrastructure that delivers real-world value and advances critical cancer research.
- AI in cancer research has enabled breakthroughs like reducing patient recovery times and achieving a 100% success rate in a colon cancer clinical trial.
Siliconangle | 21 Nov, 2024
Powered by
Compare Memorial Sloan Kettering Cancer Center with
Cognizant
3.7
Capgemini
3.7
HDFC Bank
3.9
Infosys
3.6
ICICI Bank
4.0
HCLTech
3.5
Tech Mahindra
3.5
Genpact
3.8
Teleperformance
3.9
Concentrix Corporation
3.8
Axis Bank
3.8
Amazon
4.1
Jio
4.0
iEnergizer
4.6
Reliance Retail
3.9
IBM
4.0
LTIMindtree
3.8
HDB Financial Services
3.9
Larsen & Toubro Limited
4.0
Deloitte
3.8
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Memorial Sloan Kettering Cancer Center
Infosys
Consulting, IT Services & Consulting
3.6
• 40k reviews
ICICI Bank
Financial Services, Banking
4.0
• 38.6k reviews
HCLTech
Telecom, Education & Training, Hardware & Networking, Banking, Emerging Technologies, IT Services & Consulting, Software Product
3.5
• 36.8k reviews
Tech Mahindra
BPO/KPO, Consulting, Analytics & KPO, Engineering & Construction, IT Services & Consulting
3.5
• 35.6k reviews
Genpact
Financial Services, EdTech, IT Services & Consulting
3.8
• 32k reviews
Teleperformance
BPO, IT Services & Consulting, Software Product
3.9
• 30.2k reviews
Memorial Sloan Kettering Cancer Center FAQs
What are the pros and cons of working in Memorial Sloan Kettering Cancer Center?
Working at Memorial Sloan Kettering Cancer Center comes with several advantages and disadvantages. It is highly rated for work life balance and work satisfaction. However, it is poorly rated for skill development, promotions / appraisal and salary & benefits, based on 5 employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
